Aralez Pharma, Anchored In Cardiovascular, Will Be Prowling For Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
The new company, to be formed through the merger of Pozen and Tribute, will develop a commercial organization to sell Yosprala and look to bring in new assets through licensing and M&A.